Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapy Against HPV16/18 Generates Potent T <sub>H</sub> 1 and Cytotoxic Cellular Immune Responses

10 Oct 2012

Abstract excerpt

Despite the development of highly effective prophylactic vaccines against human papillomavirus (HPV) serotypes 16 and 18, prevention of cervical dysplasia and cancer in women infected with high-risk HPV serotypes remains an unmet medical need. We report encouraging phase 1 safety, tolerability, and immunogenicity results for a therapeutic HPV16/18 candidate vaccine, VGX-3100, delivered by in vivo electroporation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23052295
DOI: 10.1126/scitranslmed.3004414

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunotherapy Against HPV16/18 Generates Potent T <sub>H</sub> 1 and Cytotoxic Cellular Immune ResponsesPMID 23052295Read ↗

DNA vaccines for cervical cancer: from bench to bedsideSemantic proximity Read ↗

Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.Semantic proximity Read ↗

A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins.Semantic proximity Read ↗

DNA Immunotherapy for Recurrent Respiratory Papillomatosis (RRP): Phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107Semantic proximity Read ↗

Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancerSemantic proximity Read ↗

Adenovirus vector‐based prime‐boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteinsSemantic proximity Read ↗

[What clinicians should know about human papilloma virus vaccines].Semantic proximity Read ↗

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vectorSemantic proximity Read ↗

Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trialSemantic proximity Read ↗

Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltrationSemantic proximity Read ↗

Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated MalignanciesSemantic proximity Read ↗

A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.